MedTrace Logo

CEQUA for Sjogren's Syndrome Dry Eye

NCT04835623 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-04-16

No results posted yet for this study

Summary

The primary objective of this study is to show that CEQUA (cyclosporine 0.09% ophthalmic solution) improves symptoms of dry eye disease in a population of patients with Sjogren's Syndrome diagnosis.

Conditions

  • Dry Eye
  • Dry Eye Syndromes
  • Sjogren's Syndrome

Interventions

DRUG

Cyclosporine 0.09% Ophthalmic Solution

one drop each eye twice daily

Sponsors & Collaborators

  • Sun Pharmaceutical Industries Limited

    collaborator INDUSTRY

  • Center for Ophthalmic and Vision Research, LLC

    lead OTHER

Principal Investigators

  • John Rocco Robilotto, OD, PhD · Center for Ophthalmic and Vision Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-21
Primary Completion
2024-03-21
Completion
2024-03-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04835623 on ClinicalTrials.gov